GE9.F
Price:
$196.55
Market Cap:
$90.65B
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2000-10-23
Stock Exchange
XETRA
Ticker
GE9.F
According to Genmab A/S’s latest financial reports and current stock price. The company's current Current Ratio is 5.34. This represents a change of 2.77% compared to the average of 5.20 of the last 4 quarters.
The mean historical Current Ratio of Genmab A/S over the last ten years is 13.46. The current 5.34 Current Ratio has changed 3.87% with respect to the historical average. Over the past ten years (40 quarters), GE9.F's Current Ratio was at its highest in in the March 2018 quarter at 23.99. The Current Ratio was at its lowest in in the June 2024 quarter at 5.03.
Average
13.46
Median
14.69
Minimum
5.25
Maximum
18.52
Discovering the peaks and valleys of Genmab A/S Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 109.88%
Maximum Annual Current Ratio = 18.52
Minimum Annual Increase = -60.67%
Minimum Annual Current Ratio = 5.25
Year | Current Ratio | Change |
---|---|---|
2024 | 5.25 | -60.67% |
2023 | 13.34 | -14.29% |
2022 | 15.57 | 7.35% |
2021 | 14.50 | -3.31% |
2020 | 15.00 | 0.76% |
2019 | 14.88 | -11.22% |
2018 | 16.77 | -9.49% |
2017 | 18.52 | 55.65% |
2016 | 11.90 | 34.45% |
2015 | 8.85 | 109.88% |
The current Current Ratio of Genmab A/S (GE9.F) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
11.38
5-year avg
12.73
10-year avg
13.46
Genmab A/S’s Current Ratio is
Company | Current Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genmab A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genmab A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Genmab A/S's Current Ratio?
How is the Current Ratio calculated for Genmab A/S (GE9.F)?
What is the highest Current Ratio for Genmab A/S (GE9.F)?
What is the 3-year average Current Ratio for Genmab A/S (GE9.F)?
What is the 5-year average Current Ratio for Genmab A/S (GE9.F)?
How does the current Current Ratio for Genmab A/S (GE9.F) compare to its historical average?